CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Institute of Hematology & Blood Diseases Hospital, China
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Fondazione Italiana Linfomi - ETS
Comenius University
University of Utah
Centre Hospitalier Universitaire de Nice
Virogen Biotechnology Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Wisconsin, Madison
Mayo Clinic
University of Miami
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Affiliated Hospital to Academy of Military Medical Sciences
Fred Hutchinson Cancer Center
Nurix Therapeutics, Inc.
Dana-Farber Cancer Institute
University of Nebraska
Arovella Therapeutics Ltd
St. Justine's Hospital
New York State Psychiatric Institute
University of Arizona
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Novartis
Affiliated Hospital of Nantong University
Fudan University
Henan Cancer Hospital
Massachusetts General Hospital
Eli Lilly and Company
Fudan University
Brown University
Sheba Medical Center
University Hospital, Angers
Massachusetts General Hospital
M.D. Anderson Cancer Center
Sun Yat-sen University
Institute of Hematology & Blood Diseases Hospital, China
Dizal Pharmaceuticals
Children's Oncology Group